

Donor 2882

Genetic Testing Summary

Fairfax Cryobank recommends reviewing this genetic testing summary with your healthcare provider to determine suitability.

Last Updated: 03/24/22

Donor Reported Ancestry: Scottish, Welsh, English, Irish, German, French, African American

Jewish Ancestry: No

enetic Test*	Result	Comments/Donor's Residual Risk**	
--------------	--------	----------------------------------	--

Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/ and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping of 97 mutations in the CFTR gene	1/343
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/632
Tay Sachs enzyme analysis	Non-carrier by Hexosaminidase A activity	

^{*}No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

^{**}Donor residual risk is the chance the donor is still a carrier after testing negative.



Cystic Filosis Mutation Analysis

Patient Name: Donor # 2882

Referring Physician:

Specimen #:

Client # Case #:

DOB: Not Given

Sex: M SSN: Date Collected: 11/30/2009 Date Received: 12/01/2009


Lab ID: Hospital ID:

Specimen Type: BLDPER

Ethnicity: Caucasian

Indication: Carrier test / Gamete donor

RESULTS: Negative for the 97 mutations analyzed



INTERPRETATION

This individual's risk to be a carrier is reduced from 1/25 (4%) to 1/343 (0.3%), based on these results and a negative family history.

COMMENTS:

Mutation Detection Rates among Ethnic Groups Detection rates are based on mutation frequencies in patients affected with cystic fibrosis. Among individuals with an atypical or mild presentation (e.g. congenital absence of the vas deferens, pancreatitis) detection rates may vary from those provided here.				
Ethnicity	Carrier risk reduction when no family history	Detection rate	References	
African American	1/65 to 1/338	81%	Genet in Med 3:168, 2001	
Ashkenazi Jewish	1/26 to 1/834	97%	Am J Hum Genet 51:951, 1994	
Asian		Not Provided	Insufficient data	
Caucasian	1/25 to 1/343	93%	Genet in Med 3:168, 2001; Genet in Med 4:90, 2002	
Hispanic	1/46 to 1/205	78%	Genet in Med 3:168, 2001;www.dhs.ca.gov/pcfh/gdb/html/PDE/CFStudy.htm	
Jewish, non-Ashkenazi		Varies by country of origin	Genet Testing 5:47, 2001, Genet Testing, 1:35, 1997	
Other or Mixed Ethnicity		Not Provided	Detection rate not determined and varies with ethnicity	

This interpretation is based on the clinical and family relationship information provided and the current understanding of the molecular genetics of this condition.

METHOD

DNA is isolated from the sample and tested for the 97 CF mutations listed. Regions of the CFTR gene are amplified enzymatically and subjected to a solution-phase multiplex allele-specific primer extension with subsequent hybridization to a bead array and fluorescent detection. The assay discriminates between $\Delta F508$ and the following polymorphisms: F508C, I506V and I507V. In some cases, specific allele identification requires enzymatic amplification followed by hybridization to oligonucleotide probes.

Under the direction of:

SMAC

Marasimhan Nagan, Ph.D., FACMG

12.16.09

Date: 12/08/2009

Page 1 of 1



SMN1 Cor Number Analysis

606452 / 366220

Fairfax Cryobank

Patient Name: . Donor # 2882

DOB:

Age:

SSN #:

Gender: Male

Genzyme Specimen

Case #:

Patient ID #:

Date Collected: 11/30/2009

Date Received: 12/01/2009

Referring Physician: Steve Pool

Genetic Counselor:

Client Lab ID #: Hospital ID #: Specimen ID #:

Specimen Type: Peripheral Blood

Specimen(s) Received: 2 - Yellow (ACD) 10 ml round

bottom tube(s)

Clinical Data: Carrier Test/Gamete donor

Ethnicity: Caucasian

RESULTS: SMN1 copy number: 2 (Reduced Carrier Risk)

INTERPRETATION:

This individual has an SMN1 copy number of two. This result reduces but does not eliminate the risk to be a carrier of SMA. Ethnic specific risk reductions based on a negative family history and an SMN1 copy number of two are provided in the Comments section of this report.

COMMENT:

Spinal muscular atrophy (SMA) is an autosomal recessive disease of variable age of onset and severity caused by mutations (most often deletions or gene conversions) in the survival motor neuron (SMN1) gene. Molecular testing assesses the number of copies of the SMN1 gene. Individuals with one copy of the SMN1 gene are predicted to be carriers of SMA. Individuals with two or more copies have a reduced risk to be carriers. (Affected individuals have 0 copies of the SMN1 gene.)

This copy number analysis cannot detect individuals who are carriers of SMA as a result of either 2 (or very rarely 3) copies of the SMN1 gene on one chromosome and the absence of the SMN1 gene on the other chromosome or small intragenic mutations within the SMN1 gene. This analysis also will not detect germline mosaicism or mutations in genes other than SMN1. Additionally, de novo mutations have been reported in approximately 2% of SMA patients.

Carrier Frequency and Risk Reductions for Individuals with No Family History of SMA						
Ethnicity	Detection Rate ¹	A priori Carrier Risk ¹	Reduced Carrier Risk for 2 copy result	Reduced Carrier Risk for 3 copy result		
Caucasian	94.9%	1:35	1:632	1:3,500		
Ashkenazi Jewish	90.2%	1:41	1:350	1:4,000		
Asian	92.6%	1:53	1:628	1:5,000		
Hispanic	90.6%	1:117	1:1061	1:11,000		
African American	71.1%	1:66	1:121	1:3,000		
Mixed Ethnicities	For counseling purposes, consider using the ethnic background with the most conservative risk estimates.					

METHOD/LIMITATIONS:

METHOD/LIMITATIONS:
Specimen DNA is isolated and amplified by real-time polymerase chain reaction (PCR) for exon 7 of the SMN1 gene and two reference genes. A mathematical algorithm is used to calculate the number of copies of SMN1. Sequencing of the primer and probe binding sites for the SMN1 real-time PCR reaction is performed on all fetal samples, and on samples from individuals with 1 copy of SMN1 on carrier testing, to rule out the presence of sequence variants which could interfere with analysis and interpretation. False positive or negative results may occur for reasons that include genetic variants, blood transfusions, bone marrow transplantation, erroneous representation of family relationships or contamination of a fetal sample with maternal cells.

REFERENCES:

1. Carrier frequency and detection rate are calculated based on analysis of allele frequencies among > 1000 individuals from each ethnic group noted (Genzyme Genetics, data submitted for publication). 2. Online review of SMA: http://www.genereviews.org/profiles/sma

The test was developed and its performance characteristics have been determined by Genzyme. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test must be used in conjunction with clinical assessment, when available.

12.16.0

Electronically Signed by: Narasimhan Nagan, Ph.D., FACMG, on 12/03/2009



Tay achs Enzyme Analysis

Patient Name: Donor #2882

Referring Physician:

Specimen #:

Patient ID:

Client #:


DOB: Not Given

SSN:

Date Collected: 11/30/2009 Date Received: 12/01/2009

Lab ID: Hospital ID:

Specimen Type: White Blood Cells



RESULTS:

Hexosaminidase Activity: 1317 nmol/mg protein

Hexosaminidase Percent A: 55.2

Plasma/Serum

WBC

Expected Non-Carrier Range:

Hex A

>55%

>55%

Expected Carrier Range:

Hex A

20 - 48%

20 - 49%

INTERPRETATION: NON CARRIER

This result is within the non-carrier range for Tay-Sachs disease. Less than 0.1% of patients having non-carrier levels of Hexosaminidase-A activity are Tay-Sachs carriers.

NOTE: Maximum sensitivity and specificity for Tay-Sachs disease carrier testing are achieved by using enzymology and DNA mutation analysis together.

Under the direction of:

Stanford Marenberg, Ph.D.

Date: 12/04/2009

Page 1 of 1